Drug Trial Radar · NCT06977737
A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours
Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
Mar 21, 2025
Primary completion
Dec 31, 2029
Study completion Dec 31, 2034
Sponsor
- Lead sponsor
- Accession Therapeutics LimitedIndustry
- Sponsor type
- Industry
- First posted
- May 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ATTR-01 is the experimental drug being studied in the ATTEST clinical trial. The drug is made from a common cold virus that has been changed to only infect and multiply in cancer cells. This virus delivers an immune therapy drug into the cancer that is intended to promote a participant's own immune system to attack the cancer. The first part of this trial (sub-protocol A) is a phase 1 trial including dose escalation and expansion at one or more doses. It is the first time that ATTR-01 will be given to humans. If an optimal dose is identified, additional sub-protocols will be added by to further elicit whether ATTR-01 may successfully treat cancer. Expanded access is not available.
Conditions
- Solid Tumor, Adult
Interventions
ATTR-01Drug
Intravenous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- • Incidence of treatment emergent adverse events (AEs) [safety and tolerability]Time frame: 1 year, 2 years and 5 years
- • Determination of the optimal dose of ATTR-01Time frame: 1 year, 2 years and 5 years
- • Objective Response Rate (ORR) [Evaluation of the anti-tumour activity of ATTR-01 per RECIST V1.1]Time frame: 1 year, 2 years and 5 years
- Duration of Response (DoR) [Evaluation of the anti-tumour activity of ATTR-01 per RECIST V1.1]Time frame: 1 year, 2 years and 5 years
Locations
8 sites in 2 countries. Site status is shown where the registry gives one.
START Barcelona
Barcelona, Spain · Recruiting
Start Fjd
Madrid, Spain · Recruiting
Start Hm Ciocc
Madrid, Spain · Recruiting
General Hospital San Pedro - START
Rioja, Spain · Not yet recruiting
, St James' University Hospital
Leeds, United Kingdom · Recruiting
Churchill Hospital
Oxford, United Kingdom · Recruiting
Beatson West of Scotland Cancer Centre
Glasgow, Scotland, United Kingdom · Recruiting
Velindre Cancer Centre
Cardiff, Wales, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.